BusinessWire has been designated by BioNJ as its preferred distributor of news releases to the life sciences news media and investment community.

• SAFE-BioPharma® Standard to be Highlighted at Molecular TriCon
  FORT LEE, N.J.--(BUSINESS WIRE)--SAFE-BioPharma interoperable digital identities in assuring secure cloud computing will be featured at Cambridge Healthtech Institute's Molecular Medicine Tri-Conference
• Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results
  WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2011.     $ in millions, except EPS amounts   FourthQuarter2011   FourthQuarter2010   Year EndedDec. 31,2011   Year EndedDec. 31,2010 Sales   $12,294   $12,094   $48,047   $45,987 GAAP EPS   0.49   (0.17)   2.02   0.28 Non-GAAP EPS that excludes items listed below1   0.97   0.88   3.77   3.42 GAAP Net Income (Lo
• NPS Pharmaceuticals Announces FDA Acceptance of New Drug Application for GATTEX® (teduglutide) for the Treatment of Adult Short Bowel Syndrome (SBS)
  BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced the U.S. Food and Drug Administration (FDA) has accepted and filed for review the company’s New Drug Application (NDA) for GATTEX® (teduglutide) for the treatment of adults with short bowel syndrome or SBS. SBS is a rare disorder characterized by inadequate absorption of fluids and nutrien